GSK1034702

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Cognitive Disorders

Phase 1

Safety, Tolerability and Pharmacokinetics of GSK1034702 in Healthy Subjects

CompletedNCT00743405

GlaxoSmithKlineCognitive Disorders

Start: 2008-05-02End: 2008-12-15Updated: 2017-07-21

Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study

CompletedNCT00937846

GlaxoSmithKlineCognitive Disorders

Start: 2009-07-15End: 2009-08-28Updated: 2017-06-27

Related Papers

An evaluation of the brain distribution of [11C]GSK1034702, a muscarinic-1 (M1) positive allosteric modulator in the living human brain using positron emission tomography

EJNMMI Research2014-12-0131 citations